| Literature DB >> 33109429 |
Uwe Matterne1, Nina Egger2, Jana Tempes2, Christina Tischer3, Jonas Lander4, Marie-Luise Dierks4, Eva-Maria Bitzer2, Christian Apfelbacher5.
Abstract
OBJECTIVE: The aim of this rapid scoping review, for which only studies from the general population were considered, was to describe the extent of existing research on HL in the context of previous coronavirus outbreaks (SARS-CoV-1, MERS-CoV and SARS-CoV-2).Entities:
Keywords: Coronavirus; Epidemic; Health literacy; Pandemic; Scoping review
Mesh:
Year: 2020 PMID: 33109429 PMCID: PMC7547635 DOI: 10.1016/j.pec.2020.10.012
Source DB: PubMed Journal: Patient Educ Couns ISSN: 0738-3991
Fig. 1PRISMA 2009 Flow Diagram [28].
Health literacy (HL) and behavioural dimensions assessment in quantitative studies.
| SARS-CoV-2 | SARS-CoV-1 | MERS-CoV | ||
|---|---|---|---|---|
| Functional HL | Knowledge | 7 [ | 25 [ | 21 [ |
| Awareness | 2 [ | 3 [ | 9 [ | |
| Nature | 2 [ | 10 [ | 9 [ | |
| Transmission | 4 [ | 18 [ | 18 [ | |
| Symptoms | 6 [ | 8 [ | 13 [ | |
| Course | 2 [ | 4 [ | 7 [ | |
| Treatment | 2 [ | 5 [ | 8 [ | |
| Risk groups | 1 [ | 0 | 3 [ | |
| Fatality rate/# infections | 2 [ | 1 [ | 3 [ | |
| Measures of infection control | 0 | 1 [ | 1 [ | |
| Prevention | 4 [ | 3 [ | 8 [ | |
| Attitude | 7 [ | 28 [ | 17 [ | |
| Risk perception | 4 [ | 20 [ | 18 [ | |
| Self-efficacy/skills/preparedness | 3 [ | 8 [ | 3 [ | |
| Critical HL | 5 [ | 11 [ | 4 [ | |
| Communicative HL | 3 [ | 12 [ | 17 [ | |
| HISB | 2 [ | 4 [ | 2 [ | |
| Behaviour/practices | 4 [ | 18 [ | 10 [ | |
| Wash hands | 1 [ | 13 [ | 9 [ | |
| Wear mask | 3 [ | 15 [ | 7 [ | |
| Avoid touching face | 0 | 3 [ | 4 [ | |
| Cough/Sneeze hygiene | 1 [ | 7 [ | 6 [ | |
| Correct tissue disposal | 0 | 0 | 3 [ | |
| Self-impose quarantine if experiencing symptoms | 0 | 1 [ | 2 [ | |
| Consult doctor if experiencing symptoms | 0 | 5 [ | 1 [ | |
| Avoid sharing personal items | 1 [ | 6 [ | 0 | |
| Avoid travelling | 0 | 3 [ | 0 | |
| Avoid travelling to high-risk areas | 0 | 2 [ | 0 | |
| Avoid public transport | 0 | 4 [ | 0 | |
| Avoid crowded places | 2 [ | 5 [ | 1 [ | |
| Avoid eating out | 0 | 3 [ | 0 | |
| Avoid people with flu-like symptoms | 0 | 2 [ | 2 [ | |
| General personal self-care (pro-active HB) | 0 | 6 [ | 0 | |
| Home hygiene | 0 | 7 [ | 1 [ | |
| Avoid camel exposure and products | 0 | 0 | 3 [ | |
| Other behavioural responses | 2 [ | 7 [ | 3 [ | |
HB: health behaviour; HISB: health-information seeking behaviour; note: cited references do not correspond to number of studies but publications.
| Study ID | Country | n | When conducted | Design | Method | Sampling | HL specific | Other theory guided | Type of theory |
|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 | |||||||||
| Betsch 2020 [ | GER | 1000 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Geldsetzer 2020a 2020b [ | UK, USA | 5974 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Khan 2020 [ | PAK | 302 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Ma 2020 [ | AUS | 28 | during | qual. | Focus groups | Conv. | no | no | n.a. |
| Nguyen 2020 [ | VNM | 3974 | during | obs cross | Quest. | Conv. | yes | no | n.a. |
| Okan 2020 [ | GER | 1000 | during | obs cross | Quest. | repr. | yes | no | n.a. |
| Roy 2020 [ | IND | 662 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Wang 2020a | CHN | 1738 | during | obs Pp | Quest. | Conv. | no | no | n.a. |
| Wolf 2020 [ | USA | 630 | during | obs cross | Quest. | Conv. | yes | no | n.a. |
| Zhong 2020 [ | CHN | 6919 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| SARS-CoV-1 | n.a. | ||||||||
| Bener 2004 [ | QAT | 1386 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Bergeron 2005 [ | CAN | 300 | post | obs cross | Quest. | Conv. | no | no | n.a. |
| Blendon 2004 [ | CAN, USA | 1500 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Brug 2004 [ | NLD | 373 | during | obs cross | Quest. | unclear | no | no | n.a. |
| Cava 2005 [ | CAN | 21 | during | qual. | Interview | Conv. | no | no | n.a. |
| Chan 2007 [ | HKG | 296/122 | during | obs Pp Intervention | Quest. | Conv. | no | no | n.a. |
| Cheng 2006 [ | CHN, SGP, HKG, CAN | 300 | during | obs Pp | Quest. | Conv. | no | yes | THB |
| Chuo 2014 [ | TWN | 294/88 | partly during (first survey wave) | obs Pp | Quest. | Conv. | no | yes | THB |
| Des Jarlais 2006/2005 [ | USA | 928 | during | obs cross | Quest. | repr. | no | yes | OM |
| Deurenberg-Yap 2005 [ | SGP | 853 | during | obs cross | Quest. | repr. | no | yes | OM |
| Hazreen 2005 [ | MYS | 201 house holds | during | obs cross | Quest. | repr. | no | no | n.a. |
| Ishizaki 2004 [ | JPN | 821 | during | obs cross | Quest. | Conv. | no | yes | THB |
| Jiang 2009 [ | UK, NLD | 164 | post | Qual. | Focus groups | Conv. | no | yes | GT |
| Lau 2003 [ | HKG | 1397 | during | obs Pp | Quest. | repr. | no | yes | THB |
| Lau 2005 [ | HKG | 820 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Lau 2004 [ | HKG | 820 | during | obs cross | Quest. | Conv. | no | yes | THB |
| Leung 2003 [ | HKG | 1115 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Leung 2005 [ | HKG | 4481 | post | obs Pp | Quest. | repr. | no | no | n.a. |
| Leung 2004/2009 [ | HKG, SGP | 1906 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Lim 2003 [ | SGP | 101 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Peng 2010 [ | TWN | 1278 | post | obs cross | Quest. | repr. | no | no | n.a. |
| Quah 2004 [ | SGP | 1201 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Seng 2004 [ | SGP | 593 | post | obs cross | Quest. | Conv. | no | no | n.a. |
| Siu 2016 [ | HKG | 40 | post | qual. | interview | Conv. | no | no | n.a. |
| So 2004 [ | HKG | 163/112 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Tan 2004 [ | CHN | 1807 | during | obs retros | Quest. | Conv. | no | no | n.a. |
| Tang 2003 [ | HKG | 2331 | during | obs cross | Quest. | Conv. | no | yes | THB |
| Tang 2005 [ | HKG | 354 | during | obs cross | Quest. | Conv. | no | yes | THB |
| Tracy 2009 [ | CHN | 500 | post | obs cross | Quest. | Conv. | no | yes | PHM |
| Tse 2003 [ | HKG | 40 | during | qual. | interview | Conv. | no | no | n.a. |
| Vartti 2009 [ | NLD, FIN | 681 | during | obs cross | Quest. | Conv. | no | yes | MISR |
| Voeten 2009 [ | UK, NLD | 300 | post | obs cross | Quest. | Conv. | no | yes | THB |
| Wills 2008 [ | CAN | 19 | during | qual. | interview | Conv. | no | no | |
| Wong 2005 [ | HKG | 230 | during | obs cross | Quest. | repr. | no | yes | THB |
| Yip 2007 [ | HKG | 463 | during | obs cross | Quest. | Conv. | no | no | |
| Zwart 2009 [ | DNK,NLD, UK, ESP, POL, SGP, CHN, HKG | 3436 | during | obs cross | Quest. | repr. | no | yes | THB |
| MERS-CoV | |||||||||
| Al-Hazmi 2018 [ | SAU | 1109 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Al-Mohaissen 2017 [ | SAU | 1541 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Alhomoud 2017 [ | SAU | 292/257 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Almutairi 2015 [ | SAU | 1147 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Alotaibi 2017 [ | SAU | 417 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Alqahtani 2016a/2016b [ | AUS | 421 | during | obs Pp | Quest. | Conv. | no | yes | THB |
| Alqahtani 2017 [ | SAU, KWT, UAE, QAT, BHR, OM | 1812 | during | obs cross | Quest. | Conv. | no | yes | THB |
| Althobaity 2017 [ | SAU | 2120 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Ashok 2016 [ | SAU | 404 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Bawazir 2018 [ | SAU | 676 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Gautret 2013 [ | FRA | 360 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Hoda 2016 [ | SAU | 854/658 | during | obs cross | Quest. | repr. | no | yes | CPM |
| Hou 2018 [ | SGP | 2969 | during | obs cross | Quest. | Conv. | no | yes | THB |
| Jang 2018 [ | KOR | 1036 | during | obs cross | Quest. | repr. | no | yes | THB |
| Kamau 2019 [ | KEN | 22 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Kim 2018 [ | KOR | 814 | during | obs cross | Quest. | Conv. | no | yes | VBM |
| Lee 2019 [ | KOR | 855 | post | obs cross | Quest. | repr. | no | no | n.a. |
| Lee 2016 [ | KOR | 6739 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Lin 2017 [ | USA | 627 | both | obs cross | Quest. | repr. | no | no | n.a. |
| Migault 2019 [ | FRA | 82 | during | obs Pp Intervention | Quest. | Conv. | no | no | n.a. |
| Nooh 2010 [ | SAU | 384 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Sahin 2015 [ | TUR | 381 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Tashani 2014 [ | AUS | 119 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Yang 2017 [ | KOR | 1470 | during | obs cross | Quest. | Conv. | no | no | n.a. |
| Yang 2019 [ | KOR | 222,599 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Yoo 2016 [ | KOR | 1000 | during | obs cross | Quest. | repr. | no | no | n.a. |
| Health Literacy | HISB | Behaviour/practice | Instrument validated | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Functional | Critical | Commu-nicative | |||||||
| Know-ledge | Atti-tude* | Risk perc-eption† | Skills‡ | ||||||
| SARS-CoV-2 | |||||||||
| Betsch 2020 [ | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | n.r. |
| Geldsetzer 2020a 2020b [ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | n.r. |
| Khan 2020 [ | 25CF; | 25CF; | ○ | ○ | ○ | 25CF; | ○ | 25CF; | n.r. |
| Ma 2020 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | 25CF; | 25CF; | n.a. |
| Nguyen 2020 [ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | 25CF; | partly |
| Okan 2020 [ | ○ | ○ | ○ | 25CF; | 25CF; | 25CF; | ○ | ○ | n.r. |
| Roy 2020 [ | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | n.r. |
| Wang 2020a | 25CF; | 25CF; | 25CF; | ○ | 25CF; | ○ | ○ | ○ | partly |
| Wolf 2020 [ | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | n.r. |
| Zhong 2020 [ | ○ | ○ | ○ | ○ | 25CF; | ○ | ○ | ○ | n.r. |
| SARS-1 | |||||||||
| Bener 2004 [ | 25CF; | 25CF; | ○ | ○ | 25CF; | 25CF; | 25CF; | 25CF; | n.r. |
| Bergeron 2005 [ | 25CF; | 25CF; | ○ | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Blendon 2004 [ | 25CF; | 25CF; | ○ | ○ | ○ | 25CF; | 25CF; | 25CF; | n.r. |
| Brug 2004 [ | 25CF; | ○ | 25CF; | 25CF; | 25CF; | 25CF; | ○ | 25CF; | n.r. |
| Cava 2005 [ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | 25CF; | |
| Chan 2007 [ | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Cheng 2006 [ | 25CF; | 25CF; | ○ | 25CF; | ○ | ○ | 25CF; | 25CF; | n.r. |
| Chuo 2014 [ | ○ | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | n.r. |
| Des Jarlais 2006/2005 [ | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | n.r. |
| Deurenberg-Yap 2005 [ | 25CF; | 25CF; | 25CF; | ○ | 25CF; | ○ | ○ | ○ | n.r. |
| Hazreen 2005 [ | 25CF; | 25CF; | 25CF; | ○ | 25CF; | 25CF; | ○ | 25CF; | n.r. |
| Ishizaki 2004 [ | 25CF; | 25CF; | 25CF; | ○ | 25CF; | 25CF; | ○ | ○ | n.r. |
| Jiang 2009 [ | 25CF; | 25CF; | 25CF; | 25CF; | ○ | 25CF; | 25CF; | 25CF; | n.a. |
| Lau 2003 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | 25CF; | n.r. |
| Lau 2005 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | n.r. |
| Lau 2004 [ | f0a1; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Leung 2003 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Leung 2005 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | f02d;○ | ○ | 25CF; | n.r. |
| Leung 2004/2009 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Lim 2003 [ | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | n.r. |
| Peng 2010 [ | ○ | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | ○ | ○ | n.r. |
| Quah 2004 [ | 25CF; | 25CF; | 25CF; | ○ | 25CF; | ○ | ○ | 25CF; | n.r. |
| Seng 2004 [ | 25CF; | ○ | ○ | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Siu 2016 [ | ○ | 25CF; | ○ | ○ | ○ | ○ | ○ | 25CF; | n.a. |
| So 2004 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Tan 2004 [ | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Tang 2003 [ | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | n.r. |
| Tang 2005 [ | ○ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | 25CF; | n.r. |
| Tracy 2009 [ | ○ | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | n.r. |
| Tse 2003 [ | 25CF; | ○ | ○ | ○ | ○ | 25CF; | ○ | ○ | n.a. |
| Vartti 2009 [ | 25CF; | 25CF; | 25CF; | ○ | 25CF; | 25CF; | 25CF; | 25CF; | n.r. |
| Voeten 2009 [ | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | ○ | ○ | n.r. |
| Wills 2008 [ | ○ | 25CF; | 25CF; | ○ | ○ | 25CF; | 25CF; | 25CF; | n.a. |
| Wong 2005 [ | ○ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | 25CF; | n.r. |
| Yip 2007 [ | ○ | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | n.r. |
| Zwart 2009 [ | ○ | 25CF; | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | n.r. |
| MERS | |||||||||
| Al-Hazmi 2018 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Al-Mohaissen 2017 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Alhomoud 2017 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Almutairi 2015 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | 25CF; | n.r. |
| Alotaibi 2017 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Alqahtani 2016a/2016b [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | 25CF; | n.r. |
| Alqahtani 2017 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | 25CF; | n.r. |
| Althobaity 2017 [ | 25CF; | ○ | 25CF; | ○ | ○ | ○ | ○ | ○ | n.r. |
| Ashok 2016 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | n.r. |
| Bawazir 2018 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Gautret 2013 [ | 25CF; | 25CF; | ○ | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Hoda 2016 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Hou 2018 [ | 25CF; | 25CF; | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Jang 2018 [ | 25CF; | 25CF; | 25CF; | 25CF; | ○ | 25CF; | 25CF; | 25CF; | n.r. |
| Kamau 2019 [ | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Kim 2018 [ | 25CF; | 25CF; | 25CF; | 25CF; | 25CF; | ○ | ○ | ○ | n.r. |
| Lee 2019 [ | ○ | ○ | ○ | ○ | ○ | 25CF; | ○ | 25CF; | n.r. |
| Lee 2016 [ | ○ | 25CF; | ○ | ○ | ○ | ○ | ○ | 25CF; | n.r. |
| Lin 2017 [ | 25CF; | ○ | ○ | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Migault 2019 [ | 25CF; | ○ | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Nooh 2010 [ | 25CF; | ○ | 25CF; | ○ | ○ | 25CF; | ○ | ○ | n.r. |
| Sahin 2015 [ | 25CF; | 25CF; | ○ | ○ | ○ | ○ | ○ | ○ | n.r. |
| Tashani 2014 [ | 25CF; | ○ | ○ | ○ | 25CF; | 25CF; | ○ | ○ | n.r. |
| Yang 2017 [ | 25CF; | 25CF; | 25CF; | ○ | 25CF; | ○ | ○ | 25CF; | n.r. |
| Yang 2019 [ | ○ | ○ | ○ | ○ | ○ | 25CF; | ○ | 25CF; | n.r. |
| Yoo 2016 [ | ○ | ○ | 25CF; | 25CF; | ○ | 25CF; | ○ | ○ | n.r. |